糖皮质激素对免疫相关性神经疾病患者血浆、CSF可溶性凋亡基因的影响

Effects of Glucocortioid on sFas in the Plasma and CSF of Patients with Im- muno - Neurologic Diseases

目的:探讨糖皮质激素(GC)对免疫相关性神经疾病(IND)患者血浆、CSF可溶性凋亡基因(soluble Fas,sFas/sApo-1/sCD95)的影响。方法:双抗体夹心ELISA法检测22例IND患者GC治疗前后血浆、CSF中sFas含量,并与20例脑梗死(NIND)患者、18例手术(OP)患者、11例未用GC的重症肌无力患者(NMG)的sFas进行对比。结果:治疗前IND组、NIND组、OP组、NMG组的sFas四组之间无显著差别(血浆:F=2.04,P>0.05;CSF:F=1.94,P>0.05);各组之间两两比较无显著差别(全部P>0.05)。治疗前IND组低于治疗后IND组(血浆:t=1.478,P>0.05;CSF:t=1.133,P>0.05);治疗后:IND组高于NMG组(血浆:t=1.341,P>0.05;CSF:t=1.031,P>0.05)。结论:未发现GC对IND患者血浆、CSF的sFas有明显影响,这也许是GC有效治疗IND的原理之一,GC在IND细胞凋亡中的作用需进一步研究。

Objective: To study the effects of glucocorticoid (GC) on sFas in the plasma and cerebrospinal fluid (CSF) of the patients with immuno - neurologic diseases(IND). Methods: In this study ELISA test of double antibody sandwich assay was used to test sFas in the plasma and CSF of the 22 patients with IND before and after the GC treatment, and then the results were compared with the sFas of 20 patients with cerebral infarction (non - immuno - neurologic diseases, NIND), 18 operation patients (OP) who had no neurologic diseases and 11 patients of myasthenia gravis (MG) who were given anti -cholinesterase drugs but not GC (NMG). Results: There were no significant differences among sFas of the four groups of IND, NND, OP and NMG before the treatment (Plasma:F = 2.04, P,0.05: CSF: F=1.94, P,0.05). It was lower in IND group before the treatment than that in the same group after the treatment (Plasma: t = 1. 478, P ,0. 05: CSF: t = 1.133,F,0.05): and after treatment it was higher in IND group than that in NMG group (Plasma:t = 1.478, P>0.05: CSF: t = 1.031: P>0.05). Conclusion: There were no significant effects of GC on sFas in the plasma and CSF of the patients with IND. It may be one of the therapeutic mechanisms to IND. Further study is necessary.